15 December 2016  
EMA/CHMP/590711/2016  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Cinryze 
c1-esterase inhibitor, human 
On 15 December 2016, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Cinryze. The marketing authorisation holder for this medicinal product is Shire Services BVBA. 
The CHMP adopted an extension to an existing indication as follows:2 
“Treatment and pre-procedure prevention of angioedema attacks in adults and, adolescents 12 to 
17and children (2 years old and above) with hereditary angioedema (HAE). 
Routine prevention of angioedema attacks in adults and, adolescents 12 to 17and children (6 years 
old and above) with severe and recurrent attacks of hereditary angioedema (HAE), who are 
intolerant to or insufficiently protected by oral prevention treatments, or patients who are 
inadequately managed with repeated acute treatment.” 
Detailed recommendations for the use of this product will be described in the updated summary of product 
characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), 
and will be available in all official European Union languages after a decision on this change to the marketing 
authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days 
from adoption of the opinion 
2 New text shown in bold; removed text as strikethrough 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
                                                
